Ceramides and Fatty Acids for Dogs' Skin Barrier: Evidence

Canine atopic dermatitis is associated with abnormalities in the epidermal barrier, so ceramides, fatty acids and lipid-based products are often marketed as “skin-barrier support.” Dog studies show that some topical lipid formulations can alter barrier-related measures and may provide modest adjunctive clinical benefit. Evidence for oral ceramide supplements, however, is much weaker.

The key distinction is that changing the skin barrier—or a marker such as transepidermal water loss—does not automatically mean a dog will itch less.

Key takeaways

• Topical lipid/ceramide products have been studied in dogs with atopic dermatitis.
• Clinical benefits have generally been modest or inconsistent.
• Oral essential fatty acids have more evidence than oral ceramide supplements.
• Barrier measurements such as TEWL are not equivalent to symptom relief.
• These approaches are adjunctive, not substitutes for diagnosis and standard management of atopic dermatitis.

What does “skin barrier” mean?

The outer skin layer helps limit water loss and blocks environmental irritants. Ceramides and other lipids are important components of that barrier.

Dogs with atopic dermatitis can have abnormal stratum corneum lipid organization. That provides a plausible reason to study barrier-focused therapies—but mechanism alone does not establish clinical efficacy.

What randomized topical studies found

A randomized double-blind placebo-controlled study of 26 privately owned atopic dogs tested a topical lipid complex. Clinical scores and barrier measurements were followed during treatment.

Another randomized double-blind pilot used a topical blackcurrant emulsion containing essential fatty acids, ceramides and 18-beta glycyrrhetinic acid in dogs with mild to moderate nonseasonal atopic dermatitis. Fourteen treated and 14 placebo dogs completed the study. At one month, a ≥50% reduction in pruritus occurred more often in the treatment group, but the difference did not persist at later months. CADESI and TEWL did not show significant between-group improvement.

That is a good example of why a transient pruritus signal should not be turned into a broad claim that the product “repairs the barrier.”

What guidelines say

The 2015 ICADA guideline update concluded that lipid-containing topical formulations had inconsistent trial outcomes and insufficient evidence to recommend them as monotherapy. Oral essential fatty acids could provide a small benefit, but no particular EFA combination, dose, ratio or formulation had demonstrated clear superiority.

The 2023 AAHA allergic-skin-disease guidelines include barrier-support products, essential fatty acids and dermatologic diets as adjunctive options within multimodal management.

Oral ceramides are a different evidence question

Published oral glucosylceramide evidence in dogs includes case-level reporting, which is far weaker than randomized placebo-controlled evidence.

Therefore:

topical ceramide/lipid evidence ≠ oral ceramide supplement evidence

and:

barrier marker change ≠ clinical symptom improvement

Dog Supplement Facts evidence status

MIXED for topical barrier-directed products.

INSUFFICIENT for generic oral ceramide supplementation.

What the evidence does not prove

• all ceramide products improve canine atopic dermatitis;
• oral ceramides have the same evidence as topical lipids;
• lower TEWL automatically means less pruritus;
• barrier products can replace anti-inflammatory or antipruritic therapy when needed.

Related Dog Supplement Facts content

• Dog Skin & Coat Guide
• How to Check a Dog Skin & Coat Supplement Label
• Zinc for Dogs’ Skin
• Does Fish Oil Improve a Dog’s Skin and Coat?

References

1. Hobi S, et al. The effects of a topical lipid complex therapy on dogs with atopic dermatitis: a double blind, randomized, placebo-controlled study. Veterinary Dermatology. 2017. PMID 28220545.
2. Marsella R, et al. Randomized, double-blinded, placebo-controlled pilot study on a topical blackcurrant emulsion enriched in essential fatty acids and ceramides. Veterinary Dermatology. 2017;28(6):577-e140. PMID 28736984.
3. Olivry T, et al. Treatment of canine atopic dermatitis: 2015 updated guidelines from ICADA. 2015.
4. Miller J, et al. 2023 AAHA management of allergic skin diseases in dogs and cats guidelines. Journal of the American Animal Hospital Association. 2023;59(6):255–284. PMID 37883677.
5. Onuma M, et al. A case of canine atopic dermatitis administered with oral glucosylceramide supplementation. 2008.